Navigation Links
Protect Pharmaceutical Corporation Appoints Chief Executive Officer and Chief Financial Officer
Date:4/26/2011

PRINCETON, N.J., April 26, 2011 /PRNewswire/ -- Protect Pharmaceutical Corporation (OTCBB: PRTT) today announced its Board of Directors has appointed current Chief Operating Officer Ramesha Sesha as its Chief Executive Officer and Chairman of the Board, effective immediately. Mr. Sesha joined Protect as the Chief Operating Officer and Board Member in March 2011, following the Patent Acquisition Agreement with Nectid Inc where he was the Founder and CEO.

Mr. Sesha has over 15 years experience in both the brand and generic pharmaceutical industry. He is an Organic chemist and was the Senior Vice President for Intellectual Property and US FDA Submissions, with Wockhardt Limited in Bedminster, New Jersey. His role included managing the IP portfolio, R & D strategy and was a part of the M & A team. He founded Nectid Inc, a privately held R & D firm and has licensed or sold 19 patents to different pharmaceutical companies in the last 24 months.

Mr. Sesha's promotion reflects Protect's strategy to ensure its scientific and corporate visions are aligned together.

The Board of Directors also approved the appointment of Keith Elison to become and serve as the Company's Chief Financial Officer, to be effective immediately.  Mr. Elison has more than eleven years of experience in public company accounting and SEC compliance and reporting issues.  His professional experience includes providing accounting and financial reporting assistance for small and medium-sized publicly held companies.

About Protect Pharmaceuticals Corporation.

Based in Princeton, New Jersey, Protect (PRTT) is a publicly held drug discovery and new product development company.  Protect applies its proprietary drug delivery and discovery technologies to discover and develop clinically effective drugs. Protect is building a robust pipeline of product candidates based on its proprietary technologies, scientific knowledge and clinical expertise.  For more information, visit www.protectpharm.com.

Safe Harbor Statement

This news release may contain certain forward-looking statements and information concerning Protect's business, operations, financial condition and prospects.  These statements are subject to various risks and uncertainties.  Actual results could differ materially from those currently anticipated due to a number of factors.  The information set forth herein should be read in light of such risks and uncertainties.  The Company assumes no duty or obligation to update these statements at any future date.


'/>"/>
SOURCE Protect Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GOPs Big Pharma Protection to Cost NC Taxpayers "Hundreds of Millions"
2. Patients -- Not ERs and Big Pharma -- Need Protection
3. DMC Cardiovascular Institute First in Midwest to Implant New "Protecta" Defibrillator in a Cardiac Patient
4. Reportlinker Adds Neuroprotection - Drugs, Markets and Companies
5. Use of a Simple Three-Step Process and Prevention Algorithm to Protect Skin Shown to Reduce Pressure Ulcers
6. Joyant-Licensed Technology Earns Broad Patent Protection
7. Protect Pharma Sells Patent Portfolio to Grunenthal GmbH
8. CeNeRx Announces FDA IND Approval for its Neuroprotective Agent in Chemotherapy-Induced Neuropathy and Results From First Human Study
9. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
10. Good Clostridia in the Gut Protect from Allergy and Autoimmunity
11. Published Study Concludes: Vented Baby Bottles Protect Essential Nutrients in Breast Milk and Formula
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... ... excited to announce the next generation for LASIK in Manhattan with Contoura Vision, ... most technologically advanced laser systems available in the United States to correct nearsightedness ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... Community”: a gripping look at the religious stand in the sensitive matter ... love and compassion. “The Ministry of Reconciliation: A Compassionate and Realistic Approach to ...
(Date:9/25/2017)... ... ... The trend-spotters, tastemakers, and healthy lifestyle product experts at the New ... with the new NEXTY Gold Award at the Natural Products Expo East trade show ... is reserved for just those companies that hit high marks on the criteria of ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... September 28, 2017 to deliver a powerful message of teamwork, unity and collaboration ... Feature film writer/director Robert Adetuyi (Beat the World, Stomp the Yard) and Grammy-nominated ...
(Date:9/24/2017)... Michigan (PRWEB) , ... September 23, 2017 , ... Throughout ... do no harm. , Every day, physicians, nurses and other providers work to ... treatments and innovative industry processes. , But U.S. Senators today are threatening to ...
Breaking Medicine News(10 mins):